The group’s MASH candidate lanifibranor carries hefty sales forecasts but Inventiva might run out of cash before the approval trial reports.

A look at the depth of clinical responses seen with various MASH therapies suggests that Madrigal could eventually face serious competition.

US FDA clears first MASH (formerly NASH) therapy, nearly four years after one had been initially anticipated. With the accelerated approval path established, Madrigal gets the opportunity to create a marketplace with Rezdiffra (resmetirom), and candidates in the pipeline get a clear target.

As the first approved MASH (formerly NASH) therapy, nearly four years after initially anticipated, Madrigal gets the opportunity to establish a MASH marketplace with Rezdiffra (resmetirom).